0 Absorption and Merger Party
Securities Code: 600332
Securities Abbreviation: Guangzhou Pharmaceutical
Listing Location: Shanghai Stock Exchange
Absorbed Party
Securities Code: 000522
Securities Abbreviation: Baiyunshan A
Listing Location: Shenzhen Stock Exchange
Guangzhou Pharmaceutical Co., Ltd. Share Swap Absorption Merger Report with Guangzhou Baiyunshan Pharmaceutical Co., Ltd., Issuance of Shares to Purchase Assets and Related Transactions Report (Cancelled)
Absorption Party: Guangzhou Pharmaceutical Co., Ltd.
Address: No. 45, Shamen North Street, Liwan District, Guangzhou, Guangdong Province
Absorbed Party: Guangzhou Baiyunshan Pharmaceutical Co., Ltd.
Address: No. 88, Yunxiang Road, Tonghe Street, Baiyun District, Guangzhou, Guangdong Province
Counterparty: Guangzhou Pharmaceutical Group Co., Ltd.
Address: No. 45, Shamen North Street, Liwan District, Guangzhou, Guangdong Province
Independent Financial Advisor:
Address: 29th Floor, Shanghai Bank Building, No. 168, Yincheng Middle Road, Shanghai
December 2012
1 Statement
The Board of Directors and all directors of the company guarantee that the content of this report and its summary is true, accurate, and complete, and bear individual or joint legal responsibility for any false records, misleading statements, or significant omissions in this report and its summary. The person in charge of the company and the person in charge of accounting work, as well as the head of the accounting institution, guarantee that the financial accounting reports in this report and its summary are true and complete. Any decisions or opinions made by the China Securities Regulatory Commission and other government departments regarding this major asset restructuring do not indicate a substantive judgment or guarantee regarding the value of the company's stock or the returns for investors. Any contrary statements are false and misleading. After the completion of this major asset restructuring, the changes in the company's operations and earnings are the company's own responsibility; the investment risks arising from this restructuring are the responsibility of the investors themselves. Investors who have any questions about this report and its summary should consult their stock brokers, lawyers, professional accountants, or other professional advisors. All information disclosed in this report is for the reference of investors in the domestic A-share market in China and does not constitute any offer, commitment, opinion, or suggestion regarding the issuance of shares or asset restructuring to any other market investors.